病例报告：度普利尤单抗治疗大疱性类天疱疮
Case report: Dupilumab for the treatment of bullous pemphigoid.
作者信息
Wang Mengxin, Wang Juan, Shi Bingjun
机构信息
Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine (Chongqing Clinical Research Center for Dermatology; Chongqing Key Laboratory of Integrative Dermatology Research), Chongqing, People's Republic of China.
Department of Graduate School, Guizhou University of Traditional Chinese Medicine, Guiyang, People's Republic of China.
出版信息
Dermatol Ther. 2022 Jul;35(7):e15541. doi: 10.1111/dth.15541. Epub 2022 May 13.
Bullous pemphigoid (BP) is an inflammatory subepidermal blistering disease with rising prevalence in the elderly individuals. Cytokines associated with Th2-type immune response play an important role in the pathogenesis of BP. The traditional glucocorticoids and immunosuppressants are recommended as first-line drugs, but their therapeutic use is limited by numerous adverse effects. Dupilumab is a humanized monoclonal antibody that targets IL-4 and IL-13. It has recently been approved for the treatment of atopic dermatitis and may be an attractive therapeutic option for BP as well. Herein, we report two cases of BP treated with dupilumab. It was effective and well tolerated. Further research is needed to assess the efficacy of dupilumab in BP patients.
大疱性类天疱疮（BP）是一种炎症性表皮下大疱性疾病，在老年人中的患病率呈上升趋势。与Th2型免疫反应相关的细胞因子在BP的发病机制中起重要作用。传统的糖皮质激素和免疫抑制剂被推荐作为一线药物，但其治疗应用受到众多不良反应的限制。度普利尤单抗是一种靶向IL-4和IL-13的人源化单克隆抗体。它最近已被批准用于治疗特应性皮炎，也可能是BP的一种有吸引力的治疗选择。在此，我们报告两例用度普利尤单抗治疗的BP病例。它有效且耐受性良好。需要进一步研究来评估度普利尤单抗在BP患者中的疗效。
Zotero 插件